期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 217, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113314
关键词
PLK; Inhibitor; Target; Inhibitory activity
资金
- Project of Shandong Medical and Health Science and Technology [2019WS393]
- Natural Science Foundation of Shandong Province [ZR2020QH344]
Polo-like kinases (PLKs) are important in regulating cell cycle and proliferation, and dysregulation in cancers can lead to uncontrolled proliferation and poor prognosis. Targeting PLKs along with other cancer-related targets is considered a rational and potent strategy to enhance therapy effectiveness in cancer treatment.
Polo-like kinases (PLKs) play important roles in regulating multiple aspects of cell cycle and cell proliferation. In many cancer types, PLK family members are often dysregulated, which can lead to uncontrolled cell proliferation and aberrant cell division and has been shown to associate with poor prognosis of cancers. The key roles of PLK kinases in cancers lead to an enhanced interest in them as promising targets for anticancer drug development. In consideration of PLK inhibitors and some other anticancer agents, such as BRD4, EEF2K and Aurora inhibitors, exert synergy effects in cancer cells, dualtargeting of PLK and other cancer-related targets is regarded as an rational and potent strategy to enhance the effectiveness of single-targeting therapy for cancer treatment. This review introduces the PLK family members at first and then focuses on the recent advances of single-target PLK inhibitors and summarizes the corresponding SARs of them. Moreover, we discuss the synergisms between PLK and other anti-tumor targets, and sum up the current dual-target agents based on them. (C) 2021 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据